Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1.
摘要：
The SBG 2000-1 trial is a randomised study that investigates if dose-tailored adjuvant FEC therapy based on the individual's leukocyte nadir value can improve outcome. The study has included 1535 women with medium and high-risk breast cancer.
展开
关键词：
Humans Carcinoma Breast Neoplasms Cyclophosphamide Epirubicin Treatment Outcome Chemotherapy, Adjuvant Severity of Illness Index Feasibility Studies Individuality
DOI：
10.3109/0284186X.2011.554435
被引量：
年份：
2011
Taylor & Francis
Taylor & Francis
(全网免费下载)
国家科技图书文献中心
(权威机构)
万方医学
www.ingentaconnect.com
查看更多
Europe PMC
NCBI
Informa Healthcare
ResearchGate
EBSCO
forskning.regionh.dk
deepdyve.com
pubfacts.com
forskningsdatabasen.dk
regiongavleborg.se
researchweb.org
fou.nu
uu.diva-portal.org
mysciencework.com
bvsalud.org
lg.se
gup.ub.gu.se
jove.com
swepub.kb.se
Taylor & Francis
(全网免费下载)
通过文献互助平台发起求助，成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
来源期刊
引用走势
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
